About
Cancer Barrier Penetrating Therapies
Areas of Focus
Categories
Boston & New England
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
1
As Collaborator
2
Total Enrollment
473
By Phase
PHASE2: 2PHASE1: 1
By Status
RECRUITING: 2COMPLETED: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT06189209Collaborator
Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)
PHASE2Recruiting
40 participants
Started: Mar 4, 2024 · Completed: Mar 31, 2026
NCT05753722Lead Sponsor
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
PHASE1Recruiting
270 participants
Started: Mar 3, 2023 · Completed: Sep 30, 2027
NCT05007236Collaborator
Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection.
PHASE2Completed
163 participants
Started: Sep 20, 2021 · Completed: Mar 25, 2022
Locations (1)
Headquarters
Boston, MA, United States
Map
Loading map...